Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study
Emerging data suggest suboptimal antibody responses to COVID-19 vaccination in patients with hematological malignancies. We evaluated the humoral response following the BNT162b2 vaccine in patients with chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), and Hodgkin’s lymphoma (HL). An...
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-09-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/17/4480 |
id |
doaj-3b9da709129e42f890b769a03faacc5d |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Evangelos Terpos Maria Gavriatopoulou Despina Fotiou Chara Giatra Ioannis Asimakopoulos Maria Dimou Aimilia D. Sklirou Ioannis Ntanasis-Stathopoulos Ismini Darmani Alexandros Briasoulis Efstathios Kastritis Maria Angelopoulou Ioannis Baltadakis Panayiotis Panayiotidis Ioannis P. Trougakos Theodoros P. Vassilakopoulos Maria Pagoni Meletios A. Dimopoulos |
spellingShingle |
Evangelos Terpos Maria Gavriatopoulou Despina Fotiou Chara Giatra Ioannis Asimakopoulos Maria Dimou Aimilia D. Sklirou Ioannis Ntanasis-Stathopoulos Ismini Darmani Alexandros Briasoulis Efstathios Kastritis Maria Angelopoulou Ioannis Baltadakis Panayiotis Panayiotidis Ioannis P. Trougakos Theodoros P. Vassilakopoulos Maria Pagoni Meletios A. Dimopoulos Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study Cancers SARS-CoV-2 COVID-19 vaccination BNT162b2 vaccine chronic lymphocytic leukemia non-Hodgkin’s lymphoma Hodgkin’s lymphoma |
author_facet |
Evangelos Terpos Maria Gavriatopoulou Despina Fotiou Chara Giatra Ioannis Asimakopoulos Maria Dimou Aimilia D. Sklirou Ioannis Ntanasis-Stathopoulos Ismini Darmani Alexandros Briasoulis Efstathios Kastritis Maria Angelopoulou Ioannis Baltadakis Panayiotis Panayiotidis Ioannis P. Trougakos Theodoros P. Vassilakopoulos Maria Pagoni Meletios A. Dimopoulos |
author_sort |
Evangelos Terpos |
title |
Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study |
title_short |
Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study |
title_full |
Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study |
title_fullStr |
Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study |
title_full_unstemmed |
Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study |
title_sort |
poor neutralizing antibody responses in 132 patients with cll, nhl and hl after vaccination against sars-cov-2: a prospective study |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2021-09-01 |
description |
Emerging data suggest suboptimal antibody responses to COVID-19 vaccination in patients with hematological malignancies. We evaluated the humoral response following the BNT162b2 vaccine in patients with chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), and Hodgkin’s lymphoma (HL). An FDA-approved, ELISA-based methodology was implemented to evaluate the titers of neutralizing antibodies (NAbs) against SARS-CoV-2 on day 1 of the first vaccine, and afterwards on day 22 and 50. One hundred and thirty-two patients with CLL/lymphomas and 214 healthy matched controls vaccinated during the same period, at the same center were enrolled in the study (NCT04743388). Vaccination with two doses of the BNT162b2 vaccine led to lower production of NAbs against SARS-CoV-2 in patients with CLL/lymphomas compared with controls both on day 22 and on day 50 (<i>p</i> < 0.001 for all comparisons). Disease-related immune dysregulation and therapy-related immunosuppression are involved in the low humoral response. Importantly, active treatment with Rituximab, Bruton’s tyrosine kinase inhibitors, or chemotherapy was an independent prognostic factor for suboptimal antibody response. Patients with HL showed superior humoral responses to the NHL/CLL subgroups. In conclusion, patients with CLL/lymphomas have low humoral response following COVID-19 vaccination, underlining the need for timely vaccination ideally during a treatment-free period and for continuous vigilance on infection control measures. |
topic |
SARS-CoV-2 COVID-19 vaccination BNT162b2 vaccine chronic lymphocytic leukemia non-Hodgkin’s lymphoma Hodgkin’s lymphoma |
url |
https://www.mdpi.com/2072-6694/13/17/4480 |
work_keys_str_mv |
AT evangelosterpos poorneutralizingantibodyresponsesin132patientswithcllnhlandhlaftervaccinationagainstsarscov2aprospectivestudy AT mariagavriatopoulou poorneutralizingantibodyresponsesin132patientswithcllnhlandhlaftervaccinationagainstsarscov2aprospectivestudy AT despinafotiou poorneutralizingantibodyresponsesin132patientswithcllnhlandhlaftervaccinationagainstsarscov2aprospectivestudy AT charagiatra poorneutralizingantibodyresponsesin132patientswithcllnhlandhlaftervaccinationagainstsarscov2aprospectivestudy AT ioannisasimakopoulos poorneutralizingantibodyresponsesin132patientswithcllnhlandhlaftervaccinationagainstsarscov2aprospectivestudy AT mariadimou poorneutralizingantibodyresponsesin132patientswithcllnhlandhlaftervaccinationagainstsarscov2aprospectivestudy AT aimiliadsklirou poorneutralizingantibodyresponsesin132patientswithcllnhlandhlaftervaccinationagainstsarscov2aprospectivestudy AT ioannisntanasisstathopoulos poorneutralizingantibodyresponsesin132patientswithcllnhlandhlaftervaccinationagainstsarscov2aprospectivestudy AT isminidarmani poorneutralizingantibodyresponsesin132patientswithcllnhlandhlaftervaccinationagainstsarscov2aprospectivestudy AT alexandrosbriasoulis poorneutralizingantibodyresponsesin132patientswithcllnhlandhlaftervaccinationagainstsarscov2aprospectivestudy AT efstathioskastritis poorneutralizingantibodyresponsesin132patientswithcllnhlandhlaftervaccinationagainstsarscov2aprospectivestudy AT mariaangelopoulou poorneutralizingantibodyresponsesin132patientswithcllnhlandhlaftervaccinationagainstsarscov2aprospectivestudy AT ioannisbaltadakis poorneutralizingantibodyresponsesin132patientswithcllnhlandhlaftervaccinationagainstsarscov2aprospectivestudy AT panayiotispanayiotidis poorneutralizingantibodyresponsesin132patientswithcllnhlandhlaftervaccinationagainstsarscov2aprospectivestudy AT ioannisptrougakos poorneutralizingantibodyresponsesin132patientswithcllnhlandhlaftervaccinationagainstsarscov2aprospectivestudy AT theodorospvassilakopoulos poorneutralizingantibodyresponsesin132patientswithcllnhlandhlaftervaccinationagainstsarscov2aprospectivestudy AT mariapagoni poorneutralizingantibodyresponsesin132patientswithcllnhlandhlaftervaccinationagainstsarscov2aprospectivestudy AT meletiosadimopoulos poorneutralizingantibodyresponsesin132patientswithcllnhlandhlaftervaccinationagainstsarscov2aprospectivestudy |
_version_ |
1717760607535497216 |
spelling |
doaj-3b9da709129e42f890b769a03faacc5d2021-09-09T13:41:12ZengMDPI AGCancers2072-66942021-09-01134480448010.3390/cancers13174480Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective StudyEvangelos Terpos0Maria Gavriatopoulou1Despina Fotiou2Chara Giatra3Ioannis Asimakopoulos4Maria Dimou5Aimilia D. Sklirou6Ioannis Ntanasis-Stathopoulos7Ismini Darmani8Alexandros Briasoulis9Efstathios Kastritis10Maria Angelopoulou11Ioannis Baltadakis12Panayiotis Panayiotidis13Ioannis P. Trougakos14Theodoros P. Vassilakopoulos15Maria Pagoni16Meletios A. Dimopoulos17Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, GreeceDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, GreeceDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, GreeceBMT Unit, Department of Hematology and Lymphomas, Evangelismos General Hospital, 10676 Athens, GreeceDepartment of Hematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, GreeceFirst Propedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, GreeceDepartment of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, 15784 Athens, GreeceDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, GreeceBMT Unit, Department of Hematology and Lymphomas, Evangelismos General Hospital, 10676 Athens, GreeceDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, GreeceDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, GreeceDepartment of Hematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, GreeceBMT Unit, Department of Hematology and Lymphomas, Evangelismos General Hospital, 10676 Athens, GreeceFirst Propedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, GreeceDepartment of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, 15784 Athens, GreeceDepartment of Hematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, GreeceBMT Unit, Department of Hematology and Lymphomas, Evangelismos General Hospital, 10676 Athens, GreeceDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, GreeceEmerging data suggest suboptimal antibody responses to COVID-19 vaccination in patients with hematological malignancies. We evaluated the humoral response following the BNT162b2 vaccine in patients with chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), and Hodgkin’s lymphoma (HL). An FDA-approved, ELISA-based methodology was implemented to evaluate the titers of neutralizing antibodies (NAbs) against SARS-CoV-2 on day 1 of the first vaccine, and afterwards on day 22 and 50. One hundred and thirty-two patients with CLL/lymphomas and 214 healthy matched controls vaccinated during the same period, at the same center were enrolled in the study (NCT04743388). Vaccination with two doses of the BNT162b2 vaccine led to lower production of NAbs against SARS-CoV-2 in patients with CLL/lymphomas compared with controls both on day 22 and on day 50 (<i>p</i> < 0.001 for all comparisons). Disease-related immune dysregulation and therapy-related immunosuppression are involved in the low humoral response. Importantly, active treatment with Rituximab, Bruton’s tyrosine kinase inhibitors, or chemotherapy was an independent prognostic factor for suboptimal antibody response. Patients with HL showed superior humoral responses to the NHL/CLL subgroups. In conclusion, patients with CLL/lymphomas have low humoral response following COVID-19 vaccination, underlining the need for timely vaccination ideally during a treatment-free period and for continuous vigilance on infection control measures.https://www.mdpi.com/2072-6694/13/17/4480SARS-CoV-2COVID-19 vaccinationBNT162b2 vaccinechronic lymphocytic leukemianon-Hodgkin’s lymphomaHodgkin’s lymphoma |